While targeting PUMA holds promise, several challenges need to be addressed. One major challenge is the potential for toxicity in normal cells, as PUMA-induced apoptosis is not cancer-specific. Another challenge is the development of resistance mechanisms that can circumvent PUMA activation. Therefore, combination therapies that include PUMA activation along with other treatment modalities may be more effective.
